The group currently runs five research and development programs, notably, its sol-gel platform for nose-to-brain delivery of medical compounds including cannabinoids and dual gene therapy for curative and prevention therapies for diabetes and obesity. Last month, the firm received the first shipment of … Read More
The post PreveCeutical Medical Inc. signs non-disclosure agreement with leading drug delivery device … appeared first on Dagga Magazine.